[Long-term results of treatment of patients with bone tumors using hydroxyapatite and calcium phosphate ceramic implants].
On the basis of experimental-and-clinical investigations it has been found out that the home-produced hydroxylapatite (HA)- and tricalciumphosphate(TCP)-based ceramic material is capable owing to specificities of its chemical structure and osteoinductive action of stimulating the reparative osteogenesis and is accompanied by angiogenesis. No ill effects have been noted in its use in bone plastic surgery. An apparent clinical effect has been shown to occur in postsurgical patients (n = 120) presenting with giant cell tumour, benign tumours and tumour-like affections of the bones, with the expediency having been ascertained of employment of the HA- and TCP-base ceramic material in the treatment of the above patients. The use of the above materials implants versus allotransplants promotes decline in the percentage of complications (1.66 vs 27.2), shortening of time of medical rehabilitation of patients by two to three months as compared to allotransplantation as well as hospital stay duration (by 10 to 12 days).
Protsenko
V V
VV
Tolstop'iatov
B O
BO
Diedkov
A G
AG
Konovalenko
V F
VF
Korovin
S I
SI
Palivets'
A Iu
AIu
Volkov
I B
IB
Vasiliuk
O M
OM
D001672:Biocompatible Materials / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology / Q000628:therapy*; D002130:Calcium Phosphates / Q000737:chemistry*; D002516:Ceramics / Q000627:therapeutic use*; D015331:Cohort Studies; D017886:Durapatite / Q000737:chemistry*; D006801:Humans; D007902:Length of Stay; D008297:Male; D018919:Neovascularization, Physiologic; D010012:Osteogenesis; D011184:Postoperative Period; D019736:Prostheses and Implants
D001672:Biocompatible Materials; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; D017886:Durapatite; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous